30 results about "Autoimmunity" patented technology

The utility model relates to a detection kit of autoimmune nervous system disease, including box and with box rotation connection's box cover, the inside position adjustable of box is provided with a plurality of baffle, the both sides of each baffle upper portion respectively symmetry is provided with a plurality of clamping block, moves the baffle, makes the clamping block between adjacent two baffles clamp test tube, each baffle top is equipped with the limiting structure for fixing its position, the inside one side of box evenly interval is provided with a plurality of card slot, the baffle one side has opened first recess, and the baffle upside has opened the second recess with first recess intercommunication, the limiting structure includes the clamping block for with first recess sliding fit and with clamping block vertical connection's operating block, the operating block is away from the inner wall between second recess between clamping block one side and first recess and is equipped with the compression spring. The detection kit of autoimmune nervous system disease can clamp test tube of different diameter size, and the scope of application is wider.

The present invention relates to antigen-binding proteins, related fragments thereof, for binding to CD80, and their use for treating various conditions such as inflammation and autoimmunity.

This invention relates to MASP isotypes as inhibitors of complement activation. It also relates to novel ficolin-related peptides and peptides derived from these ficolin-related peptides for the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombosis, or coagulopathy, and for use as biomarkers. Furthermore, this invention relates to antibodies recognizing the novel ficolin-related peptides and peptides derived therefrom, nucleic acid molecules encoding the peptides, vectors for producing the peptides, and host cells.

The application discloses a polypeptide, the amino acid sequence of which is shown as SEQ ID NO: 1 or 2. The inventors find that the polypeptide has the following advantages: the recognized antigen epitope is clear, the cross-reaction is low, the selection of the antigen domain is more flexible and easy to synthesize, the cost is low, and the synthesis period is short by predicting the CXCR5 protein sequence. In addition, the polypeptide can be used for screening an anti-CXCR5 protein antibody, the obtained anti-CXCR5 protein antibody has strong binding capacity with the CXCR5 protein, the cost and period of developing the CXCR5 antibody drug can be effectively reduced, and a new strategy is provided for tumor and autoimmune disease treatment and disease diagnosis.

The application relates to a method for constructing an experimental autoimmune prostatitis rat model, which comprises the following steps: S1, preparing a prostate specific antigen mixture; S2, selecting male SD rats as experimental rats and dividing the rats into a physiological saline control group, a low-dose model group and a high-dose model group; S3, continuously injecting for 7 days, wherein the physiological saline control group receives 0.2ml of physiological saline injection every day, the low-dose model group receives 0.1ml of the prostate specific antigen mixture injection every day, and the high-dose model group receives 0.2ml of the prostate specific antigen mixture injection every day; and S4, continuing to feed all the experimental rats in the groups until the 28th day, wherein the experimental rats in the low-dose model group and the high-dose model group are induced by the prostate specific antigen mixture to cause experimental autoimmune prostatitis, and an experimental autoimmune prostatitis rat model is obtained. The method can not only reduce the use of animals and the cost, but also improve the modeling efficiency and stability.

The present application belongs to the field of nutritional composition and biological medicine technology, and particularly relates to a composition for protecting and preserving liver, a preparation method, application and product thereof. The composition of the present application is composed of extract of Silybum marianum, glucoraphanin and extract of Cynara scolymus. The composition of the present application can intervene the pathological process of liver injury from multiple dimensions such as antioxidation, anti-inflammation, regulation of lipid metabolism and repair of hepatocytes through synergistic effect of the three components, significantly reduces the levels of glutamic-pyruvic transaminase and glutamic-oxalacetic transaminase, reduces the accumulation of liver fat, improves the antioxidant capacity of the body, effectively prevents or improves alcoholic, chemical, non-alcoholic fatty and autoimmune liver injury, delays the progression of liver fibrosis, and comprehensively maintains the structural integrity and functional stability of the liver.

One of the purposes of the present application is to provide a method and a plasmid for enhancing cell adhesion. The second purpose of the present application is to provide a cell for protein expression with enhanced adhesion. The third purpose of the present application is to provide a CBA method detection kit for autoimmune encephalitis based on the aforementioned cell. The fourth purpose of the present application is to provide a CBA method detection kit for autoimmune central nervous system demyelination disease based on the aforementioned cell.

The application discloses discovery and application of desmin autoantibody as a marker of nervous system diseases. The application finds that only the fluorescent signal existing in the nervous system disease patients but not in the healthy people, and the fluorescent mode of the IgG related autoimmune antibody in the mouse brain tissue section is different, which indicates that the patient may have autoimmune antibody. Through the immunoprecipitation technology, the IgG specific protein related to the nervous system disease is sought, the specific desmin autoantibody is found by adopting the CBA mode, and then the desmin autoantibody is verified in the cerebrospinal fluid, so that it is finally determined that the desmin autoantibody can be used as a specific marker for diagnosing the nervous system autoimmune diseases. The expression of the desmin autoantibody is detected by taking the desmin as a detection antigen, and the detection of the desmin autoantibody can be applied to a kit for detecting the desmin autoantibody, and can be applied to the detection of the nervous system diseases, so that the marker for identifying the nervous system diseases is enriched, and the accuracy of the detection of the nervous system related diseases is improved.

The disclosure provide for fusion proteins, multimeric proteins, and hexamer proteins capable of use for antibody discovery and / or therapeutic vaccination in companion animals, for example, dogs and cats. The disclosure further provides for multimeric and hexameric proteins capable of the treatment of pain, for example, inflammation, neuropathic pain, diabetes-related pain, arthritic pain and autoimmunity pain, as well as dermatological disorders, for example atopic dermatitis or pruritus, in animals. Use of multimeric and hexameric proteins described herein as vaccines or immunogen is further described.

The present application belongs to the field of medicine, and particularly relates to a novel compound for treating multiple sclerosis. Specifically, the present application provides a compound as shown in formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same, wherein the compound or the salt or the pharmaceutical composition comprising the same has the biological activity of inhibiting CD4 + The biological activity of T cells differentiating into Th17 cells can be used for preventing and / or treating autoimmune deficiency diseases related to Th17 cells, for example, multiple sclerosis (MS). The compound of the present application is novel in structure, excellent in biological activity, and can be used as an ideal candidate drug compound for treating MS.

A method for generating immuno-free and stress-resistant donor cells comprising editing PRDM1 and FOXP3 genes in T-cells and B-cells with CRISPR-Cas9 and modulating immune responses to reduce inflammation and prevent autoimmunity. Particularly, the present invention discloses a method for treating Type 1 Diabetes, comprising genetically modifying pancreatic beta cells with CRISPR-Cas9, and altering HLA expression, and upregulating immune checkpoint molecules such as PD-L1 to obtain immune-tolerant and stress-resistant pancreatic beta cells.

The present disclosure relates to fusion proteins comprising a mutant IL-2 polypeptide subunit and one or two antigen binding domains (e.g., VHH antibodies) that specifically bind to an antigen expressed on the surface of immune cells such as tumor reactive T cells expressing CD8 and / or PD1. The fusion can also comprise a half-life extending protein subunit such as an Ig1 Fc region monomer polypeptide. The present disclosure also relates to the use of these fusion proteins as therapeutic agents, for example, in pharmaceutical compositions for treating cancer and autoimmune disorders.

The application provides a cell climbing sheet processing reagent for a Ranvier node / paranode antibody spectrum detection kit (cellular immunofluorescence method), a method and application thereof, and relates to the technical field of in-vitro detection. The cell climbing sheet processing reagent comprises a cell fixing solution with a specific composition and an antigen repair composition after cell fixing, wherein the cell fixing solution is composed of paraformaldehyde, formaldehyde, acetic acid, raffinose and a buffer solution, and the antigen repair composition after cell fixing is composed of ammonium sulfate, hydroxylamine hydrochloride, Brij 78, TCEP, ProClin 300 and a buffer solution. Through the synergistic effect of the two, the natural conformation of the target antigen is maximally retained, and non-specific interference is reduced, so that precise and efficient detection of the Ranvier node / paranode antibody spectrum NF155, NF186, CNTN1, CASPR1 and MAG can be realized, the clinical diagnosis demand is met, and reliable technical support is provided for precise typing of autoimmune Ranvier node disease.

The present invention relates to a compound of Formula (I) or a stereoisomer, tautomer, N-oxide, pharmaceutically acceptable salt, or solvate thereof. The compounds of Formula (I) are useful as medicaments for the treatment or prevention of autoimmune disorders or inflammatory conditions. The compounds of Formula (I) have been shown to inhibit SLC15 peptide transporter-TASL assembly by binding to SLC15 peptide transporters.

The present invention provides indazolyl-piperidine sulfamides and related compounds, pharmaceutical compositions, their use for inhibiting mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), and their use in treating diseases or conditions such as proliferative disorders, inflammatory disorders, or autoimmune disorders.

A system for evaluating a subject, including: a processor in communication with a carbon monoxide (CO) detector, and a memory in communication with the processor having stored thereon a set of instructions which, when executed by the processor, cause the processor to: receive, from the CO detector, a measure of CO in a subject suspected of having at least one of autism spectrum disorder (ASD), autoimmunity, or inflammation; obtain a level of at least one biomarker associated with the subject based on receiving the measure of CO in the subject; and generate a report based on obtaining the level of the at least one biomarker.

Disclosed herein are antibody-drug-conjugates (ADC) that allow for delivery and release of glucocorticoid receptor modulators into desired tissues. The disclosed ADCs include a peptide that facilitates the release of a glucocorticoid receptor modulator by legumain. The antibody-drug-conjugates are useful as therapeutic agents for treating various autoimmune disorders, inflammatory disorders, and blood cancers. Pharmaceutical compositions which include the ADCs are also disclosed, as are methods of treating autoimmune disorders, inflammatory disorders, and blood cancers by administering a therapeutically effective amount of an antibody-drug-conjugate disclosed herein under conditions effective to treat said disorders.

Provided herein are antibodies and antibody fragments that bind to human TNFRSF25. The antibodies may be monoclonal and / or biparatopic antibodies and / or single- chain fragment variable (scFv) antibodies. Methods of treating or preventing diseases or disorders associated with inflammation and / or autoimmunity are provided, comprising administering to a patient in need thereof an effective amount of a human TNFRSF25- binding antibody.

Screening methods are provided that are based on using ELISpot assays to measure the distribution profile of maximum spot intensity or mean spot intensity of spontaneous cytokine or chemokine or the number of "low intensity" spontaneous cytokine or chemokine producing cells as a clinically relevant measure of immune function for diagnosing patients with a particular disorder based on one or more of these measurements and for treating the particular disorder in the patient. In some embodiments, the cytokine is IFN-gamma or TNF-alpha. Patients can optionally be further evaluated to determine whether they are of an immunosuppressed or hyperinflammatory immune phenotype by quantifying cytokine and / or chemokine levels in a biological sample. Representative disorders include sepsis, autoimmune disease, autoimmunity, cancer, and lymphopenia.

This invention belongs to the pharmaceutical field, specifically relating to novel compounds that inhibit Th17 cell differentiation and their applications. Specifically, this invention provides various novel compounds, their tautomers, stereoisomers, isotope markers, hydrates, solvates, pharmaceutically acceptable salts, or prodrugs, which possess biological activity in inhibiting the differentiation of CD4+ T cells into Th17 cells and can be used for the prevention and / or treatment of Th17 cell-related autoimmune deficiency diseases (especially multiple sclerosis). The various compounds of this invention have novel structures and excellent biological activity, making them ideal candidate drug compounds for the treatment of MS.

The application relates to the field of biological medicine, and discloses a medicine for relieving autoimmune prostatitis and application thereof, which comprises an active ingredient and a pharmaceutically acceptable sterile phosphate buffer carrier; the active ingredient is live Lactobacillus johnsonii with a number of BNCC135265 or extracellular vesicles of Lactobacillus johnsonii; the final concentration of live bacteria in the medicine is 1x10 8 to 1x10 10 CFU / mL, which is used for preparing a preparation for intragastric administration; the extracellular vesicles contain 1x10 8 to 5x10 9 particles per unit dosage form, which is used for preparing a preparation for tail vein injection administration. By using the live bacteria with the specific number or the extracellular vesicles thereof, intestinal mucosa colonization can be achieved to block endotoxin into blood, or the extracellular vesicles can be enriched in prostate lesions to inhibit a nuclear factor-kappa B inflammatory signaling pathway, reduce synthesis of proinflammatory cytokines and lymphocyte infiltration, and finally realize relief of autoimmune prostatitis.

Provided herein are heteroaryl compounds, pharmaceutical compositions, and their use in the treatment of a disease or condition, such as a proliferative disorder, inflammatory disorder, autoimmune disorder, or metabolic disorder. In some embodiments, the heteroaryl compounds are represented by Formula (I), or a pharmaceutically acceptable salt thereof, wherein values for the variables (e.g., A1, A2, A3, A4, R1A) are as described herein.

The invention provides methods for upregulating mitochondrial and / or glycolytic metabolism in T cells by increasing the flux of pyruvate into the citric acid cycle, thereby increasing mitochondrial and / or glycolytic metabolism. In general these methods comprise stable expression of a transgene encoding either pyruvate dehydrogenase kinase enzyme and / or pyruvate dehydrogenase phosphatase enzyme in T cells. The invention further provides engineered T cells, preferably engineered human T cells produced by such methods, which optionally are further engineered, e.g., to express a targeting and / or therapeutic moiety and the use thereof and compositions containing in adoptive T cell therapies, e.g., the treatment and prevention of cancer, infection, inflammation, autoimmunity and neurodegenerative conditions.

Disclosed herein are antibody-drug-conjugates (ADC) that allow for delivery and release of glucocorticoid receptor modulators into desired tissues. The disclosed ADCs include a peptide that facilitates the release of a glucocorticoid receptor modulator by legumain. The antibody-drug-conjugates are useful as therapeutic agents for treating various autoimmune disorders, inflammatory disorders, and blood cancers. Pharmaceutical compositions which include the ADCs are also disclosed, as are methods of treating autoimmune disorders, inflammatory disorders, and blood cancers by administering a therapeutically effective amount of an antibody-drug-conjugate disclosed herein under conditions effective to treat said disorders.